A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.

Authors

Morten A Karsdal, Anne-Christine Bay-Jensen, Daniel Guldager Kring Rasmussen, Aleksander Krag, Stine Johansen, Quentin M Anstee, Diana J Leeming, Federica Genovese, Arun J Sanyal, Cecilie L Bager, Robert J Benschop, Salvador Augustin, Darren Ruane, Neeraj Adya, Jörn M Schattenberg, Ali Mobasheri, Veronica Miller, Maja Thiele, Roberto A Calle, Patrick Bossuyt, Adam Platt, Signe H Larsen, Kim Henriksen, Vincent Bonneau, Bruno Golding, Mohamed Hassanein, Sumanta Mukherjee, Sarah Harris, Zoltan Derdak, Suneil Hosmane, Paresh Thakker, Virginia B Kraus

Published in

Journal of hepatology. Jul 25, 2026. Epub Jul 25, 2026.

Abstract

Not all biomarkers are equal, and some should not be termed biomarkers. Despite an explosion in putative biomarker discoveries from high-throughput proteomic technologies, very few advance beyond initial excitement to become validated, clinically actionable tools. Most stall in a "biomarker valley of death," where promising signals fail to meet robust technical, scientific, and regulatory standards for clinical use. We propose a framework to distinguish between unvalidated protein findings and validated biomarkers with specific utility. We highlight the need to separate exploratory protein measurements from biomarkers that meet predefined analytical criteria and progress through validation, including qualification as Reasonably Likely Surrogate Endpoints (RLSE) or Validated Surrogate Endpoints (VSE). This expert opinion delineates differences between biomarker discovery, development, regulatory qualifications and commercialization pathways, emphasizing nomenclature according to BEST Resource (Biomarkers, EndpointS, and other Tools), analytical validation (CLSI guidelines), clinical relevance, and alignment with frameworks of the US Food and Drug Administration (FDA), specifically Premarket Approval (PMA) or Biomarker Qualification Program (BQP), and the EU's IVDR and Drug Development Tool (DDT) programs. We introduce the concept of the "Unicorn Biomarker" - an extremely rare class of biomarkers with validated multipurpose utility (diagnostic, prognostic, and pharmacodynamic/monitoring) to exemplify their value in decision-making. We propose that minimum technical and biological standards must be met before a molecular measurement can be designated a "biomarker", beyond minimal criteria of association between biological signal and disease state. By raising the bar with Unicorn Biomarkers, this framework aims to guide researchers, regulators, and industry stakeholders in identifying actionable biomarkers and advancing precision medicine.

PMID:
42501868
Bibliographic data and abstract were imported from PubMed on 26 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.